BTI-322 monoclonal antibody data

BTRN and MEDI reported Phase I/II results from a one-year follow-up period. Rejection episodes were halved

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE